BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33. [PMID: 20439566 DOI: 10.7326/0003-4819-153-1-201007060-00252] [Cited by in Crossref: 216] [Cited by in F6Publishing: 175] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu PH, Lin MY, Chiu YW, Lee JJ, Hwang SJ, Hung CC, Chen HC. Low serum iron is associated with anemia in CKD stage 1-4 patients with normal transferrin saturations. Sci Rep 2021;11:8343. [PMID: 33863963 DOI: 10.1038/s41598-021-87401-w] [Reference Citation Analysis]
2 Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65:49-57. [PMID: 25115616 DOI: 10.1053/j.ajkd.2014.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
3 Jaar BG, Chang A, Plantinga L. Can We Improve Quality of Life of Patients on Dialysis? CJASN 2013;8:1-4. [DOI: 10.2215/cjn.11861112] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
4 Uchiyama K, Mochizuki T, Shimada Y, Nishio S, Kataoka H, Mitobe M, Tsuchiya K, Hanaoka K, Ubara Y, Suwabe T, Sekine A, Nutahara K, Tsuruya K, Ishimura E, Nakatani S, Sofue T, Tanaka S, Narita I, Maruyama S, Horie S, Muto S. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD). Clin Exp Nephrol 2021;25:970-80. [PMID: 33928479 DOI: 10.1007/s10157-021-02068-x] [Reference Citation Analysis]
5 Wang J, van Bentum K, Sester U, Kaestner L. Calcium homeostasis in red blood cells of dialysis patients in dependence of erythropoietin treatment. Front Physiol 2014;5:16. [PMID: 24478727 DOI: 10.3389/fphys.2014.00016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
6 Barraclough KA, Brown F, Hawley CM, Leary D, Noble E, Campbell SB, Isbel NM, Mudge DW, van Eps CL, Johnson DW. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant 2012;27:4146-53. [PMID: 22962411 DOI: 10.1093/ndt/gfs372] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
7 Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, Califf RM, Szczech L. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant 2012;27:3606-14. [PMID: 22573238 DOI: 10.1093/ndt/gfs123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
8 Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ. What Are Rbc-Transfusion-Dependence and -Independence? Leuk Res. 2011;35:8-11. [DOI: 10.1016/j.leukres.2010.07.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
9 Zhang Y, Wu Y, Wang W, Liu F, Zhang Y, Yang C, Liu A, Wu J, Zhu T, Nicholson ML, Fan Y, Yang B. Long-Term Protection of CHBP Against Combinational Renal Injury Induced by Both Ischemia-Reperfusion and Cyclosporine A in Mice. Front Immunol 2021;12:697751. [PMID: 34381450 DOI: 10.3389/fimmu.2021.697751] [Reference Citation Analysis]
10 Haynes R, Kheradmand F, Winearls CG. Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study. Nephron Clin Pract. 2012;120:c42-c47. [PMID: 22205054 DOI: 10.1159/000334429] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014;29:1493-505. [PMID: 24005791 DOI: 10.1007/s00467-013-2557-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Richards KM, Spicer RA, Craig E, Kennedy SE. Prevalence and predictors of blood transfusion after pediatric kidney transplantation. Pediatr Nephrol 2018;33:2177-84. [PMID: 30006835 DOI: 10.1007/s00467-018-4017-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Buckley MS, Kane-gill SL, Patel SA. Clinical and Economic Evaluation of an Evidence-Based Institutional Epoetin-Utilization Management Program. Clinical Therapeutics 2013;35:294-302. [DOI: 10.1016/j.clinthera.2013.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
14 Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB; ESA Clinic Study Group. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis 2012;60:371-9. [PMID: 22633556 DOI: 10.1053/j.ajkd.2012.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
15 Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, Weiner DE. Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial. J Am Soc Nephrol 2016;27:1801-10. [PMID: 26677862 DOI: 10.1681/ASN.2015040468] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
16 Kobayashi H, Konno M, Utsugisawa T, Tanabe K, Kanno H. Preoperative autologous blood donation for kidney transplant and end-stage renal disease patients: A single-center study. Transfus Apher Sci 2021;60:103149. [PMID: 34148766 DOI: 10.1016/j.transci.2021.103149] [Reference Citation Analysis]
17 Bello NA, Lewis EF, Desai AS, Anand IS, Krum H, McMurray JJ, Olson K, Solomon SD, Swedberg K, van Veldhuisen DJ, Young JB, Pfeffer MA. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail 2015;17:1201-7. [PMID: 26423928 DOI: 10.1002/ejhf.412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
18 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Muñoz M, Gómez-Ramírez S, Besser M, Pavía J, Gomollón F, Liumbruno GM, Bhandari S, Cladellas M, Shander A, Auerbach M. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017;15:422-37. [PMID: 28880842 DOI: 10.2450/2017.0113-17] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
20 Sato Y, Yanagita M. Renal anemia: from incurable to curable. Am J Physiol Renal Physiol. 2013;305:F1239-F1248. [PMID: 23884144 DOI: 10.1152/ajprenal.00233.2013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
21 Kliger AS, Fishbane S, Finkelstein FO. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol 2012;7:354-7. [PMID: 22266571 DOI: 10.2215/CJN.11961111] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
22 Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T, Kawaguchi Y, Komatsu Y. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. J Am Soc Nephrol 2021:ASN. [PMID: 33883252 DOI: 10.1681/ASN.2020091311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. American Journal of Kidney Diseases 2016;67:820-1. [DOI: 10.1053/j.ajkd.2016.03.412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Maruyama T, Higuchi T, Yamazaki T, Okawa E, Ando H, Oikawa O, Inoshita A, Okada K, Abe M. Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. Cardiorenal Med 2017;7:188-97. [PMID: 28736559 DOI: 10.1159/000462983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
25 Locatelli F, Del Vecchio L, De Nicola L, Minutolo R. Are all erythropoiesis-stimulating agents created equal? Nephrol Dial Transplant 2021;36:1369-77. [PMID: 32206785 DOI: 10.1093/ndt/gfaa034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
26 Silverberg DS. The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev 2011;16:609-14. [DOI: 10.1007/s10741-010-9194-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
27 Granata A, Clementi A, Virzì GM, Brocca A, de Cal M, Scarfia VR, Zanoli L, Ronco C, Corrao S, Malatino L. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment. European Journal of Internal Medicine 2016;30:1-6. [DOI: 10.1016/j.ejim.2016.02.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
28 Fassett RG. Current and emerging treatment options for the elderly patient with chronic kidney disease. Clin Interv Aging 2014;9:191-9. [PMID: 24477220 DOI: 10.2147/CIA.S39763] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
29 Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Database Syst Rev 2017;8:CD010969. [PMID: 28841235 DOI: 10.1002/14651858.CD010969.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
30 Vinhas J, Barreto C, Assunção J, Parreira L, Vaz A. Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis. Nephron 2013;121:c95-c101. [DOI: 10.1159/000345158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
31 McMahon LP, MacGinley R; KHA-CARI. KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology (Carlton) 2012;17:17-9. [PMID: 22044720 DOI: 10.1111/j.1440-1797.2011.01535.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
32 Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012;59:108-116. [PMID: 21890255 DOI: 10.1053/j.ajkd.2011.07.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
33 Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Föller M, Lang F. Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl) 2014;92:871-9. [PMID: 24743961 DOI: 10.1007/s00109-014-1151-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
34 Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. [PMID: 29191165 DOI: 10.1186/s12882-017-0688-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
35 Vranješ IM, Školka I, Jakab J, Krajina I, Krajina V, Šantić A, Zibar L. Sexual function in hemodialysis and post-renal transplant women in a relationship: a cross-sectional study. Int Urol Nephrol. [DOI: 10.1007/s11255-021-03095-z] [Reference Citation Analysis]
36 Bazeley J, Wish JB. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. Adv Chronic Kidney Dis 2019;26:229-36. [PMID: 31477253 DOI: 10.1053/j.ackd.2019.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Nangaku M, Kondo K, Takabe S, Ueta K, Kaneko G, Otsuka M, Kawaguchi Y, Komatsu Y. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan. Ther Apher Dial 2021;25:642-53. [PMID: 33283981 DOI: 10.1111/1744-9987.13611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Gangat N, Wolanskyj AP. Anemia of Chronic Disease. Seminars in Hematology 2013;50:232-8. [DOI: 10.1053/j.seminhematol.2013.06.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
39 Evans M, Suttorp MM, Bellocco R, Hoekstra T, Qureshi AR, Dekker FW, Carrero JJ. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant 2016;31:628-35. [PMID: 26243782 DOI: 10.1093/ndt/gfv298] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
40 Ruospo M, Palmer SC, Craig JC, Gentile G, Johnson DW, Ford PJ, Tonelli M, Petruzzi M, De Benedittis M, Strippoli GF. Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. Nephrol Dial Transplant 2014;29:364-75. [PMID: 24081863 DOI: 10.1093/ndt/gft401] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 6.7] [Reference Citation Analysis]
41 Latcha S. Anemia management in cancer patients with chronic kidney disease. Semin Dial 2019;32:513-9. [PMID: 31596520 DOI: 10.1111/sdi.12841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Cherng YG, Lin CS, Shih CC, Hsu YH, Yeh CC, Hu CJ, Chen TL, Liao CC. Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies. PLoS One 2018;13:e0191155. [PMID: 29329323 DOI: 10.1371/journal.pone.0191155] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
43 Thavarajah S, Choi MJ. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach. American Journal of Kidney Diseases 2019;74:667-74. [DOI: 10.1053/j.ajkd.2019.04.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
44 Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2014;:CD009297. [PMID: 24683046 DOI: 10.1002/14651858.CD009297.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
45 Abraham I, MacDonald K. Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations. Expert Opin Drug Saf 2012;11:885-7. [PMID: 22998694 DOI: 10.1517/14740338.2012.726611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology (Carlton) 2017;22:548-54. [PMID: 27171136 DOI: 10.1111/nep.12815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
47 Saraf SL, Hsu JY, Ricardo AC, Mehta R, Chen J, Chen TK, Fischer MJ, Hamm L, Sondheimer J, Weir MR, Zhang X, Wolf M, Lash JP. Anemia and Incident End-Stage Kidney Disease. Kidney360 2020;1:623-30. [PMID: 33117990 DOI: 10.34067/kid.0000852020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
48 Jensen G, Gøransson LG, Fernström A, Furuland H, Christensen JH. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
. Clin Nephrol 2019;91:246-53. [PMID: 30614439 DOI: 10.5414/CN109474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
49 van Haelst IMM, Egberts ACG, Doodeman HJ, van Solinge WW, Kalkman CJ, Bennis M, Traast HS, van Klei WA. Occurrence and determinants of poor response to short-term pre-operative erythropoietin treatment: Poor response to pre-operative erythropoietin. Acta Anaesthesiol Scand 2013;57:350-7. [DOI: 10.1111/aas.12029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
50 Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 2017;1:CD011690. [PMID: 28066881 DOI: 10.1002/14651858.CD011690.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
51 Hur I, Wenziger C, Obi Y, Moradi H, Streja E, Tantisattamo E, Choi SJ, Lau WL, Chang Y, Jin A, Chen JLT, Kovesdy CP, Rhee CM, Kalantar-Zadeh K. Hemodynamic and Laboratory Changes during Incremental Transition from Twice to Thrice-Weekly Hemodialysis. Cardiorenal Med 2020;10:97-107. [PMID: 31935740 DOI: 10.1159/000504383] [Reference Citation Analysis]
52 Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263 [DOI: 10.5410/wjcu.v3.i3.258] [Reference Citation Analysis]
53 Kowalczyk M, Banach M, Mikhailidis DP, Rysz J. Erythropoietin update 2011. Med Sci Monit 2011;17:RA240-247. [PMID: 22037755 DOI: 10.12659/msm.882037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
54 de Goeij MCM, Meuleman Y, van Dijk S, Grootendorst DC, Dekker FW, Halbesma N; for the PREPARE-2 Study Group. Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. Nephrology Dialysis Transplantation 2014;29:1391-8. [DOI: 10.1093/ndt/gft533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
55 Hawwa N, Schreiber MJ Jr, Tang WH. Pharmacologic management of chronic reno-cardiac syndrome. Curr Heart Fail Rep 2013;10:54-62. [PMID: 23143732 DOI: 10.1007/s11897-012-0122-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
56 Xu L, Chen Y, Xie Z, He Q, Chen S, Wang W, Liu G, Liao Y, Lu C, Hao L, Sun J, Shi W, Liang X; China collaborative study on AKI (CCS-AKI). High hemoglobin is associated with increased in-hospital death in patients with chronic obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study. BMC Pulm Med 2019;19:174. [PMID: 31533673 DOI: 10.1186/s12890-019-0933-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Brenner N, Kommalapati A, Ahsan M, Ganguli A. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. J Nephrol 2020;33:267-75. [PMID: 31782127 DOI: 10.1007/s40620-019-00680-5] [Reference Citation Analysis]
58 Winnicki W, Prehslauer A, Kletzmayr J, Herkner H, Sunder-Plassmann G, Brunner M, Hörl WH, Sengoelge G. Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. Eur J Clin Invest 2012;42:1087-93. [PMID: 22845880 DOI: 10.1111/j.1365-2362.2012.02699.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Badve SV, Hawley CM, Johnson DW. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology (Carlton) 2011;16:144-53. [PMID: 21272125 DOI: 10.1111/j.1440-1797.2010.01407.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
60 Arantes LH Jr, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, Scotte F, Wish J. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol 2018;129:79-90. [PMID: 30097240 DOI: 10.1016/j.critrevonc.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
61 Kwon O, Jang HM, Jung HY, Kim YS, Kang SW, Yang CW, Kim NH, Choi JY, Cho JH, Kim CD, Kim YL, Park SH; Clinical Research Center for End-Stage Renal Disease (CRC- ESRD) Investigators. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS One 2015;10:e0140241. [PMID: 26452232 DOI: 10.1371/journal.pone.0140241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
62 Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I, Kono H, Nakatani E, Morita S, Tsubakihara Y, Akizawa T. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol 2016;20:71-6. [DOI: 10.1007/s10157-015-1133-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
63 Goldsmith DJ, Covic AC. Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer. Kidney Int 2011;80:237-9. [PMID: 21760602 DOI: 10.1038/ki.2011.133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Parfrey PS. Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsiveness. Semin Dial 2011;24:495-7. [PMID: 21906165 DOI: 10.1111/j.1525-139X.2011.00949.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Doodeman HJ, van Haelst IM, Egberts TC, Bennis M, Traast HS, van Solinge WW, Kalkman CJ, van Klei WA. The effect of a preoperative erythropoietin protocol as part of a multifaceted blood management program in daily clinical practice (CME). Transfusion. 2013;53:1930-1939. [PMID: 23240859 DOI: 10.1111/trf.12016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
66 Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C. Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant 2020;35:558-64. [PMID: 31028383 DOI: 10.1093/ndt/gfz058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
67 Del Vecchio L, Locatelli F. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opinion on Drug Safety 2012;11:923-31. [DOI: 10.1517/14740338.2012.712680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
68 Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831-1843. [PMID: 24856028 DOI: 10.1016/s0140-6736(14)60384-6] [Cited by in Crossref: 214] [Cited by in F6Publishing: 106] [Article Influence: 26.8] [Reference Citation Analysis]
69 Chan E, Hemmelgarn B, Klarenbach S, Manns B, Mustafa R, Nesrallah G, McQuillan R. Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question. Can J Kidney Health Dis 2017;4:2054358117695570. [PMID: 28321324 DOI: 10.1177/2054358117695570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
70 Boyle SM, Berns JS. Erythropoietin and Resistant Hypertension in CKD. Seminars in Nephrology 2014;34:540-9. [DOI: 10.1016/j.semnephrol.2014.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
71 Mikhail AI, Schön S, Simon S, Brown C, Hegbrant JBA, Jensen G, Moore J, Lundberg LDI. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO). BMC Nephrol 2019;20:13. [PMID: 30630452 DOI: 10.1186/s12882-018-1159-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29:2075-84. [PMID: 24891437 DOI: 10.1093/ndt/gfu201] [Cited by in Crossref: 149] [Cited by in F6Publishing: 127] [Article Influence: 18.6] [Reference Citation Analysis]
73 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Reference Citation Analysis]
74 Yang M, Fox CH, Vassalotti J, Choi M. Complications of progression of CKD. Adv Chronic Kidney Dis 2011;18:400-5. [PMID: 22098657 DOI: 10.1053/j.ackd.2011.10.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
75 Halawi R, Moukhadder H, Taher A. Anemia in the elderly: a consequence of aging? Expert Review of Hematology 2017;10:327-35. [DOI: 10.1080/17474086.2017.1285695] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
76 Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther 2021. [PMID: 34846711 DOI: 10.1007/s12325-021-01994-2] [Reference Citation Analysis]
77 Chillon JM, Massy ZA, Stengel B. Neurological complications in chronic kidney disease patients. Nephrol Dial Transplant 2016;31:1606-14. [PMID: 26359201 DOI: 10.1093/ndt/gfv315] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
78 Horváth-Puhó E, Suttorp MM, Frederiksen H, Hoekstra T, Dekkers OM, Pedersen L, Cannegieter SC, Dekker FW, Sørensen HT. Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. Clin Epidemiol 2018;10:1371-80. [PMID: 30310329 DOI: 10.2147/CLEP.S172306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
79 Foley RN. Levels of phosphorus and patient outcomes. Nat Rev Nephrol 2011;7:428-30. [DOI: 10.1038/nrneph.2011.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
80 Wong G, Howard K, Hodson E, Irving M, Craig JC. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrol Dial Transplant 2013;28:413-20. [PMID: 23182811 DOI: 10.1093/ndt/gfs487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
81 Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28:1346-59. [PMID: 23585588 DOI: 10.1093/ndt/gft033] [Cited by in Crossref: 210] [Cited by in F6Publishing: 176] [Article Influence: 23.3] [Reference Citation Analysis]
82 Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clin Exp Nephrol 2019;23:231-43. [PMID: 30182223 DOI: 10.1007/s10157-018-1632-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
83 Hao Z, Wu B, Wang D, Lin S, Tao W, Liu M. A cohort study of patients with anemia on admission and fatality after acute ischemic stroke. J Clin Neurosci 2013;20:37-42. [PMID: 23117142 DOI: 10.1016/j.jocn.2012.05.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
84 Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clin J Am Soc Nephrol 2020;15:608-15. [PMID: 32245781 DOI: 10.2215/CJN.08900719] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
85 Piety NZ, Reinhart WH, Stutz J, Shevkoplyas SS. Optimal hematocrit in an artificial microvascular network. Transfusion 2017;57:2257-66. [PMID: 28681482 DOI: 10.1111/trf.14213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
86 Garrido P, Ribeiro S, Fernandes J, Vala H, Rocha-Pereira P, Bronze-da-Rocha E, Belo L, Costa E, Santos-Silva A, Reis F. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. Int J Mol Sci 2015;17:E28. [PMID: 26712750 DOI: 10.3390/ijms17010028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
87 Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, Monk TG. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106:13-22. [PMID: 21148637 DOI: 10.1093/bja/aeq361] [Cited by in Crossref: 320] [Cited by in F6Publishing: 275] [Article Influence: 29.1] [Reference Citation Analysis]
88 Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
89 . Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:299-310. [PMID: 25018950 DOI: 10.1038/kisup.2012.35] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
90 Fishbane S, Hirsch JS. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19. Am J Kidney Dis 2020;76:303-5. [PMID: 32479920 DOI: 10.1053/j.ajkd.2020.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
91 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
92 Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O'Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR; American Society of Nephrology Quality, and Patient Safety Task Force. Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol 2012;7:1664-72. [PMID: 22977214 DOI: 10.2215/CJN.04970512] [Cited by in Crossref: 125] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
93 Abd El Naby SA, Bahbah WA, Kasemy ZA, Mahmoud AA. Neurophysiological and Neuroradiological Changes in Children With Chronic Kidney Disease. Front Pediatr 2020;8:570708. [PMID: 33313023 DOI: 10.3389/fped.2020.570708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Marto JP, Strambo D, Livio F, Michel P. Drugs Associated With Ischemic Stroke: A Review for Clinicians. Stroke 2021;52:e646-59. [PMID: 34404236 DOI: 10.1161/STROKEAHA.120.033272] [Reference Citation Analysis]
95 Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol 2019;1165:3-15. [PMID: 31399958 DOI: 10.1007/978-981-13-8871-2_1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
96 Kalra PA, Bhandari S, Spyridon M, Davison R, Lawman S, Mikhail A, Reaich D, Pritchard N, McCafferty K, Moore J. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol 2020;21:539. [PMID: 33302891 DOI: 10.1186/s12882-020-02180-2] [Reference Citation Analysis]
97 Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012;7:e43655. [PMID: 22952731 DOI: 10.1371/journal.pone.0043655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
98 Badve SV, Palmer SC, Strippoli GFM, Roberts MA, Teixeira-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, Johnson DW. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016;68:554-63. [PMID: 27138469 DOI: 10.1053/j.ajkd.2016.03.418] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
99 Magwood JS, Lebby A, Chen B, Kessler S, Norris L, Bennett CL. Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opinion on Emerging Drugs 2013;18:421-9. [DOI: 10.1517/14728214.2013.836490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165-180. [PMID: 21840587 DOI: 10.1016/s0140-6736(11)60178-5] [Cited by in Crossref: 934] [Cited by in F6Publishing: 455] [Article Influence: 84.9] [Reference Citation Analysis]
101 Meaney CJ, Karas S, Robinson B, Gaesser J, Forrest A, Krzyzanski W, Panesar M, Rao GG. Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. J Clin Pharmacol 2019;59:418-26. [PMID: 30412269 DOI: 10.1002/jcph.1330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Trkulja V. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices. Med Hypotheses 2012;78:157-61. [PMID: 22078846 DOI: 10.1016/j.mehy.2011.10.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
103 Stricker PA, Cladis FP, Fiadjoe JE, McCloskey JJ, Maxwell LG. Perioperative management of children undergoing craniofacial reconstruction surgery: a practice survey. Paediatr Anaesth 2011;21:1026-35. [PMID: 21595783 DOI: 10.1111/j.1460-9592.2011.03619.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
104 Macginley RJ, Walker RG. International treatment guidelines for anaemia in chronic kidney disease - what has changed? Med J Aust 2013;199:84-5. [PMID: 23879487 DOI: 10.5694/mja13.10538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
105 Biolo G, Guarnieri G, Barazzoni R, Panzetta G. Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients. Clin Exp Med 2011;11:181-7. [DOI: 10.1007/s10238-010-0119-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
106 Gluba-Brzózka A, Franczyk B, Olszewski R, Rysz J. The Influence of Inflammation on Anemia in CKD Patients. Int J Mol Sci 2020;21:E725. [PMID: 31979104 DOI: 10.3390/ijms21030725] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
107 Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Am J Nephrol. 2018;48:251-259. [PMID: 30253403 DOI: 10.1159/000493097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 Suttorp MM, Hoekstra T, Ocak G, van Diepen AT, Ott I, Mittelman M, Rabelink TJ, Krediet RT, Dekker FW. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients. Thrombosis Research 2014;134:1081-6. [DOI: 10.1016/j.thromres.2014.07.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
109 Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group. Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Can J Kidney Health Dis 2015;2:33. [PMID: 26284153 DOI: 10.1186/s40697-015-0066-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
110 Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney International 2011;80:464-74. [DOI: 10.1038/ki.2011.179] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
111 Resar LM, Wick EC, Almasri TN, Dackiw EA, Ness PM, Frank SM. Bloodless medicine: current strategies and emerging treatment paradigms. Transfusion. 2016;56:2637-2647. [PMID: 27473810 DOI: 10.1111/trf.13736] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
112 Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 2019;85:935-48. [PMID: 30677788 DOI: 10.1111/bcp.13877] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
113 Choi SR, Lim JH, Kim MY, Hong Y, Chung BH, Chung S, Choi BS, Yang CW, Kim Y, Chang YS, Park CW. Cinacalcet Improves Endothelial Dysfunction and Cardiac Hypertrophy in Patients on Hemodialysis with Secondary Hyperparathyroidism. Nephron Clin Pract 2012;122:1-8. [DOI: 10.1159/000347145] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
114 Shander A, Ozawa S, Gross I, Henry D. Erythropoiesis-stimulating agents: friends or foes? Transfusion 2013;53:1867-72. [PMID: 24015936 DOI: 10.1111/trf.12328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
115 Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017;12:e0169117. [PMID: 28046068 DOI: 10.1371/journal.pone.0169117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
116 Saglimbene V, Natale P, Palmer S, Scardapane M, Craig JC, Ruospo M, Gargano L, Lucisano G, Török M, Celia E, Gelfman R, Bednarek-Skublewska A, Dulawa J, Stroumza P, Leal M, Del Castillo D, Murgo AM, Schon S, Wollheim C, Hegbrant J, Strippoli GFM. The prevalence and correlates of low sexual functioning in women on hemodialysis: A multinational, cross-sectional study. PLoS One 2017;12:e0179511. [PMID: 28632793 DOI: 10.1371/journal.pone.0179511] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
117 Badve SV, Beller EM, Cass A, Francis DP, Hawley C, Macdougall IC, Perkovic V, Johnson DW. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev 2013;:CD006861. [PMID: 23979995 DOI: 10.1002/14651858.CD006861.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
118 Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, Pisoni R, de Moraes TP, Pecoits-Filho R, Baena CP. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol 2020;21:259. [PMID: 32641153 DOI: 10.1186/s12882-020-01912-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Maruyama Y, Yokoyama K, Yokoo T, Shigematsu T, Iseki K, Tsubakihara Y. The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. PLoS One 2015;10:e0143430. [PMID: 26599216 DOI: 10.1371/journal.pone.0143430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
120 House AA. Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment. Semin Nephrol 2012;32:40-8. [PMID: 22365161 DOI: 10.1016/j.semnephrol.2011.11.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
121 Nishiwaki H, Hasegawa T, Ikenoue T, Tominaga N, Yazawa M, Kawarazaki H, Shibagaki Y, Yamamoto Y, Fukuma S, Yamazaki S, Fukuhara S. Association between post-dialysis hemoglobin level and the survival of vascular access. J Vasc Access 2018;19:69-75. [PMID: 29076517 DOI: 10.5301/jva.5000798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
122 Schmid H, Schiffl H, Lederer SR. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2011;20:465-70. [PMID: 21738032 DOI: 10.1097/MNH.0b013e3283497057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012;60:390-401. [PMID: 22537421 DOI: 10.1053/j.ajkd.2012.03.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
124 Ben-Assa E, Shacham Y, Shashar M, Leshem-Rubinow E, Gal-Oz A, Schwartz IF, Schwartz D, Silverberg DS, Chernin G. Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study. Cardiorenal Med 2015;5:246-53. [PMID: 26648941 DOI: 10.1159/000433564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407. [PMID: 23235597 DOI: 10.1002/14651858.CD003407.pub5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
126 Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol 2011;6:1973-81. [PMID: 21784829 DOI: 10.2215/CJN.01050211] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
127 Saglimbene V, Palmer SC, Craig JC, Ruospo M, Nicolucci A, Tonelli M, Johnson D, Lucisano G, Williams G, Valentini M, D'Alonzo D, Pellegrini F, Strippoli P, Salomone M, Santoro A, Maffei S, Hegbrant J, Tognoni G, Strippoli GF; CE-DOSE Study Investigators. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. PLoS One 2017;12:e0172735. [PMID: 28249030 DOI: 10.1371/journal.pone.0172735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
128 Hammad TA, Neyarapally GA, Pinheiro SP, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: An empirical assessment. Clinical Trials 2013;10:389-97. [DOI: 10.1177/1740774513479467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
129 Kido R, Akizawa T, Fukuhara S. Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS). BMJ Open 2019;9:e031476. [PMID: 31492794 DOI: 10.1136/bmjopen-2019-031476] [Reference Citation Analysis]
130 Parfrey PS. Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. Current Opinion in Nephrology & Hypertension 2011;20:177-81. [DOI: 10.1097/mnh.0b013e3283428bc2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
131 Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Maeda K, Miyazawa Y, Hirakata H. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. Nephron 2019;143:77-85. [PMID: 31117088 DOI: 10.1159/000500487] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
132 Bonner A, Caltabiano M, Berlund L. Quality of life, fatigue, and activity in Australians with chronic kidney disease: A longitudinal study: Quality of life, fatigue, and activity. Nurs Health Sci 2013;15:360-7. [DOI: 10.1111/nhs.12038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
133 Hara T, Kimachi M, Akizawa T, Fukuhara S, Yamamoto Y. Erratum: Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. Kidney Int Rep 2021;6:1999-2007. [PMID: 34307997 DOI: 10.1016/j.ekir.2021.05.016] [Reference Citation Analysis]
134 Perrone RD, Coons SJ, Cavanaugh K, Finkelstein F, Meyer KB. Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration. Am J Kidney Dis 2013;62:1046-57. [PMID: 23988757 DOI: 10.1053/j.ajkd.2013.07.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
135 Nagai K, Yamagata K. Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease. CEN Case Rep 2016;5:117-8. [PMID: 28509181 DOI: 10.1007/s13730-016-0212-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
136 Yarnoff BO, Hoerger TJ, Simpson SA, Pavkov ME, Burrows NR, Shrestha SS, Williams DE, Zhuo X. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. PLoS One 2016;11:e0157323. [PMID: 27404556 DOI: 10.1371/journal.pone.0157323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
137 Edmonston D, Morris JD, Middleton JP. Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. Adv Chronic Kidney Dis 2018;25:454-67. [PMID: 30309463 DOI: 10.1053/j.ackd.2018.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
138 Kee YK, Jeon HJ, Oh J, Shin DH. Hypochromic red cells as predictors of anemia in patients undergoing hemodialysis: an observational retrospective study. Sci Rep 2021;11:24215. [PMID: 34931015 DOI: 10.1038/s41598-021-03746-2] [Reference Citation Analysis]
139 Nishiwaki H, Hasegawa T, Koiwa F, Hamano T, Masakane I. The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry. PLoS One 2019;14:e0210533. [PMID: 30629677 DOI: 10.1371/journal.pone.0210533] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Nistor I, Bolignano D, Haller MC, Nagler E, van der Veer SN, Jager K, Covic A, Webster A, Van Biesen W. Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice. Nephrol Dial Transplant 2017;32:1268-73. [PMID: 26497055 DOI: 10.1093/ndt/gfv365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
141 Takashima H, Maruyama T, Abe M. Significance of Levocarnitine Treatment in Dialysis Patients. Nutrients 2021;13:1219. [PMID: 33917145 DOI: 10.3390/nu13041219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 McCullough PA. Cardiorenal syndromes: pathophysiology to prevention. Int J Nephrol 2010;2011:762590. [PMID: 21151537 DOI: 10.4061/2011/762590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
143 Hsu HC, Robinson C, Norton GR, Woodiwiss AJ, Dessein PH. The Optimal Haemoglobin Target in Dialysis Patients May Be Determined by Its Contrasting Effects on Arterial Stiffness and Pressure Pulsatility. Int J Nephrol Renovasc Dis 2020;13:385-95. [PMID: 33408501 DOI: 10.2147/IJNRD.S285168] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Elliott S, Leishman B. Abuse of medicines for performance enhancement in sport: why is this a problem for the pharmaceutical industry? Bioanalysis 2012;4:1681-90. [PMID: 22831483 DOI: 10.4155/bio.12.137] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW. Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One 2013;8:e84848. [PMID: 24391978 DOI: 10.1371/journal.pone.0084848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
146 Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, Hirakata H. A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. Kidney Int Rep 2021;6:1840-9. [PMID: 34307978 DOI: 10.1016/j.ekir.2021.04.037] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
147 Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 2017;18:14. [PMID: 28077085 DOI: 10.1186/s12882-017-0438-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
148 Chen J, Gong AGW, Liu X, Li Z, Qi A, Dong TTX, Yi T, Tsim KWK, Li S. A Chinese herbal decoction, Jian-Pi-Yi-Shen, regulates the expressions of erythropoietin and pro-inflammatory cytokines in cultured cells. BMC Complement Altern Med 2018;18:119. [PMID: 29615029 DOI: 10.1186/s12906-018-2146-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
149 Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf 2016;15:1021-30. [PMID: 27149639 DOI: 10.1080/14740338.2016.1182494] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
150 Rostoker G, Hummel A, Chantrel F, Ryckelynck J. Actualités sur la prise en charge de l’anémie et de la carence martiale du dialysé. Néphrologie & Thérapeutique 2014;10:221-7. [DOI: 10.1016/j.nephro.2014.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
151 Sagheb MM, Fallahzadeh MA, Moaref A, Fallahzadeh MH, Dormanesh B. Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. Nephrourol Mon 2016;8:e38495. [PMID: 27713870 DOI: 10.5812/numonthly.38495] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
152 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
153 Reinhart WH. The optimum hematocrit. Clin Hemorheol Microcirc 2016;64:575-85. [PMID: 27767984 DOI: 10.3233/CH-168032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
154 Chaknos CM, Berns JS. Erythropoiesis-Stimulating Agents on Trial: Are Higher Dosages Causing Harm? American Journal of Kidney Diseases 2013;61:6-8. [DOI: 10.1053/j.ajkd.2012.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
155 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
156 Andrews DA, Pyrah ITG, Boren BM, Tannehill-gregg SH, Lightfoot-dunn RM. High Hematocrit Resulting from Administration of Erythropoiesis-stimulating Agents Is Not Fully Predictive of Mortality or Toxicities in Preclinical Species. Toxicol Pathol 2014;42:510-23. [DOI: 10.1177/0192623313486317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
157 Jun M, Lv J, Perkovic V, Jardine MJ. Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis 2011;2:265-78. [PMID: 23251754 DOI: 10.1177/2040622311401775] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
158 Ravani P, Quinn R, Oliver M, Robinson B, Pisoni R, Pannu N, MacRae J, Manns B, Hemmelgarn B, James M, Tonelli M, Gillespie B. Examining the Association between Hemodialysis Access Type and Mortality: The Role of Access Complications. Clin J Am Soc Nephrol 2017;12:955-64. [PMID: 28522650 DOI: 10.2215/CJN.12181116] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 12.4] [Reference Citation Analysis]
159 Kimura H, Sy J, Okuda Y, Wenziger C, Hanna R, Obi Y, Rhee CM, Kovesdy CP, Kalantar-Zadeh K, Streja E. A faster decline of residual kidney function and erythropoietin stimulating agent hyporesponsiveness in incident hemodialysis patients. Hemodial Int 2021;25:60-70. [PMID: 33034069 DOI: 10.1111/hdi.12877] [Reference Citation Analysis]
160 Del Vecchio L, Minutolo R. ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia? J Clin Med 2021;10:839. [PMID: 33670704 DOI: 10.3390/jcm10040839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H. Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Med 2013;39:1896-908. [PMID: 23928897 DOI: 10.1007/s00134-013-3030-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
162 Strippoli GF, Palmer SC, Ruospo M, Natale P, Saglimbene V, Craig JC, Pellegrini F, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Bednarek-Skublewska A, Dulawa J, Frantzen L, Ferrari JN, del Castillo D, Hegbrant J, Wollheim C, Gargano L; ORAL-D Investigators. Oral disease in adults treated with hemodialysis: prevalence, predictors, and association with mortality and adverse cardiovascular events: the rationale and design of the ORAL Diseases in hemodialysis (ORAL-D) study, a prospective, multinational, longitudinal, observational, cohort study. BMC Nephrol 2013;14:90. [PMID: 23597063 DOI: 10.1186/1471-2369-14-90] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
163 Hu Z, Tao H, Shi A, Pan J. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res 2020;20:411-8. [PMID: 32249625 DOI: 10.1080/14737167.2020.1747436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
164 Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:783-796. [PMID: 23111861 DOI: 10.1055/s-0032-1328884] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
165 Kengne AP, Czernichow S, Hamer M, Batty GD, Stamatakis E. Anaemia, haemoglobin level and cause-specific mortality in people with and without diabetes. PLoS One 2012;7:e41875. [PMID: 22876293 DOI: 10.1371/journal.pone.0041875] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
166 Stricker PA, Fiadjoe JE. Anesthesia for craniofacial surgery in infancy. Anesthesiol Clin 2014;32:215-35. [PMID: 24491658 DOI: 10.1016/j.anclin.2013.10.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
167 Ahmed SB, Dumanski SM. Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease? Canadian Journal of Cardiology 2019;35:1170-80. [DOI: 10.1016/j.cjca.2019.06.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
168 Mudge DW, Webster AC, Johnson DW. Pro: Meta-analysis: the case for. Nephrol Dial Transplant 2016;31:875-80. [DOI: 10.1093/ndt/gfw091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0114-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 16.2] [Reference Citation Analysis]
170 Sola L, Levin NW, Johnson DW, Pecoits-Filho R, Aljubori HM, Chen Y, Claus S, Collins A, Cullis B, Feehally J, Harden PN, Hassan MH, Ibhais F, Kalantar-Zadeh K, Levin A, Saleh A, Schneditz D, Tchokhonelidze I, Turan Kazancioglu R, Twahir A, Walker R, Were AJO, Yu X, Finkelstein FO. Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis. Kidney Int Suppl (2011) 2020;10:e55-62. [PMID: 32149009 DOI: 10.1016/j.kisu.2019.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
171 Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. J Nephrol 2018;31:321-32. [DOI: 10.1007/s40620-017-0419-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
172 Corsonello A, Fusco S, Bustacchini S, Chiatti C, Moresi R, Bonfigli AR, Di Stefano G, Lattanzio F. Special considerations for the treatment of chronic kidney disease in the elderly. Expert Rev Clin Pharmacol 2016;9:727-37. [PMID: 26885869 DOI: 10.1586/17512433.2016.1155448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
173 Spoto B, Kakkar R, Lo L, Devalaraja M, Pizzini P, Torino C, Leonardis D, Cutrupi S, Tripepi G, Mallamaci F, Zoccali C. Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study. J Clin Med 2019;8:E523. [PMID: 30995819 DOI: 10.3390/jcm8040523] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
174 Bellinghieri G, Condemi CG, Saitta S, Trifirò G, Gangemi S, Savica V, Buemi M, Santoro D. Erythropoiesis-stimulating agents: dose and mortality risk. J Ren Nutr 2015;25:164-8. [PMID: 25529282 DOI: 10.1053/j.jrn.2014.10.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
175 Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-brent P, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; on behalf of the FAVOURED Study Team. Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: Baseline characteristics of the FAVOURED study. Nephrology 2016;21:217-28. [DOI: 10.1111/nep.12573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
176 Wright DG, Wright EC, Narva AS, Noguchi CT, Eggers PW. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol 2015;10:1822-30. [PMID: 26358266 DOI: 10.2215/CJN.01590215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
177 Beaubrun AC, Kanda E, Bond TC, McClellan WM. Form CMS-2728 data versus erythropoietin claims data: implications for quality of care studies. Ren Fail 2013;35:320-6. [PMID: 23227806 DOI: 10.3109/0886022X.2012.747967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
178 Hodson EM, Strippoli GFM. Long- or short-acting erythropoiesis-stimulating agents: take no shortcuts in their evaluation. Nephrol Dial Transplant 2021;36:205-7. [PMID: 32582928 DOI: 10.1093/ndt/gfaa118] [Reference Citation Analysis]
179 Gowanlock Z, Sriram S, Martin A, Xenocostas A, Lazo-Langner A. Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes. Blood Adv 2017;1:1538-45. [PMID: 29296795 DOI: 10.1182/bloodadvances.2017007559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
180 Rodrigues AT, Colugnati FAB, Bastos MG. Evaluation of variables associated with the patency of arteriovenous fistulas for hemodialysis created by a nephrologist. J Bras Nefrol 2018;40:326-32. [PMID: 30080914 DOI: 10.1590/2175-8239-jbn-2017-0014] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
181 Quinn RR, Ravani P. Fistula-first and catheter-last: fading certainties and growing doubts. Nephrology Dialysis Transplantation 2014;29:727-30. [DOI: 10.1093/ndt/gft497] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
182 Warner MA, Shore-lesserson L, Shander A, Patel SY, Perelman SI, Guinn NR. Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care. Anesthesia & Analgesia 2020;130:1364-80. [DOI: 10.1213/ane.0000000000004727] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
183 Rear R, Meier P, Bell RM. Implications of Kidney Disease in the Cardiac Patient. Interv Cardiol Clin 2014;3:317-31. [PMID: 28582216 DOI: 10.1016/j.iccl.2014.03.001] [Reference Citation Analysis]
184 Hodson E, Craig JC. The contribution of systematic reviews to the practice of pediatric nephrology. Pediatr Nephrol 2013;28:197-206. [DOI: 10.1007/s00467-012-2155-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
185 Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. [PMID: 23438972 DOI: 10.1038/nrneph.2013.21] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
186 Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238-1252. [PMID: 27887750 DOI: 10.1016/s0140-6736(16)32064-5] [Cited by in Crossref: 928] [Cited by in F6Publishing: 466] [Article Influence: 154.7] [Reference Citation Analysis]
187 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
188 Petrulienė K, Žiginskienė E, Kuzminskis V, Nedzelskienė I, Bumblytė IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas) 2017;53:90-100. [PMID: 28416170 DOI: 10.1016/j.medici.2017.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
189 Hara T, Kimachi M, Akizawa T, Fukuhara S, Yamamoto Y. Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. Kidney Int Rep 2020;5:1670-8. [PMID: 33102959 DOI: 10.1016/j.ekir.2020.07.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]